Milestone Pharmaceuticals shares are trading lower after the company announced that it received a Refusal to File letter from the FDA for the New Drug Application for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia.
Portfolio Pulse from Benzinga Newsdesk
Milestone Pharmaceuticals' stock is trading lower following the FDA's Refusal to File letter for the New Drug Application of etripamil nasal spray, intended to treat paroxysmal supraventricular tachycardia.
December 26, 2023 | 1:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Milestone Pharmaceuticals' shares dropped as the FDA refused to file the New Drug Application for etripamil nasal spray, delaying its potential market entry.
The FDA's refusal to file the NDA for etripamil nasal spray is a significant regulatory setback for Milestone Pharmaceuticals, likely delaying the drug's potential approval and market entry. This news directly impacts the company's short-term prospects, as investors may have concerns about the drug's development timeline and the company's ability to bring it to market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100